Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Humacyte, Inc. (Nasdaq: HUMA) announced participation in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. CEO Laura Niklason and CFO Dale Sander will engage in a fireside chat at 12 PM ET in New York City. The event will be accessible via a live webcast, with a replay available for 30 days afterward. Humacyte is focused on developing bioengineered human tissues for treating various medical conditions, with significant advancements in acellular tissue technology, including their human acellular vessels currently in late-stage clinical trials.

DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a fireside chat at the 34^th Annual Piper Sandler Healthcare Conference taking place at the Lotte New York Palace in New York, NY, on Thursday, December 1, 2022 at 12 PM ET.

Access the live webcast here. A replay will be available for at least 30 days following the presentation at https://investors.humacyte.com/news-events/events-and-presentations.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Elizabeth Miller, M.D.
LifeSci Communications LLC
+1-646-791-9705
emiller@lifescicomms.com

FAQ

What is the date of Humacyte's participation in the Piper Sandler Healthcare Conference?

Humacyte will participate in the Piper Sandler Healthcare Conference on December 1, 2022.

Who from Humacyte will speak at the conference?

CEO Laura Niklason and CFO Dale Sander will participate in the fireside chat.

Where is the Piper Sandler Healthcare Conference taking place?

The conference will be held at the Lotte New York Palace in New York City.

How can I access the Humacyte conference presentation?

The presentation can be accessed via a live webcast, with a replay available for 30 days.

What are some key initiatives that Humacyte is working on?

Humacyte is developing acellular tissues for various applications, including vascular trauma repair and hemodialysis access.